Brief: Celcuity Reports PFS Improvement in PIK3CA WT Cohort of Phase 3 VIKTORIA-1 Breast Cancer Trial
28/07/2025 12:10
July 28 (Reuters) - Celcuity Inc CELC.O: CELCUITY ANNOUNCES CLINICALLY MEANINGFUL IMPROVEMENT IN BOTH PROGRESSION-FREE SURVIVAL (“PFS”) PRIMARY ENDPOINTS FROM PIK3CA WILD-TYPE COHORT OF PHASE 3 VIKTORIA-1 TRIAL CELCUITY- EXPECTS TO SUBMIT A NEW DRUG APPLICATION FOR GEDATOLISIB TO U.S. FDA IN Q4 OF 2025 Source text: ID:nGNX9mwxry Further company coverage: CELC.O ((Reuters.Briefs@thomsonreuters.com;))